Latebreakers: TNF-blocker Humira gets OK for juvenile rheumatoid arthritis
Adalimumab approved for polyarticular juvenile idiopathic arthritis.
Adalimumab (Humira, Abbott) may now be marketed for yet another indication – to reduce the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA), commonly referred to as juvenile rheumatoid arthritis. This marks the sixth approved indication for the biologic therapy. The new JIA approval was based on the results of a 48-week Phase III study that included 171 children with the condition, a form of arthritis that affects five or more joints, usually on one side of the body. Results showed that fewer children treated with adalimumab experienced disease flare compared with placebo. According to Abbott, JIA patients weighing 30 kg or more should use the 40-mg prefilled syringe currently used by adult patients, while children weighing between 15 kg and 29 kg should receive the 20-mg prefilled syringe dose. Adalimumab is also indicated to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and chronic plaque psoriasis. The therapy works by blocking tumor necrosis factor alpha (TNF-alpha), a key player in the inflammatory responses of some autoimmune diseases.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
